MD Anderson to collaborate with Xilis for accelerated development of new cancer therapies
Image Source:- >> | Content Source:- >> The University of Texas MD Anderson Cancer Institute and the biotech firm Xilis have entered into a strategic partnership to advance science and hasten the development of novel cancer therapies. The partnership will enhance the development of cancer therapies by combining MD...
Asieris and ReviR Therapeutics Work Together to Develop Novel Oncology Treatments
Image Source:- >> | Content Source:- >> Asieris Pharmaceuticals and ReviR Therapeutics have agreed to a research collaboration and option-to-license arrangement to develop new oncology treatments. The partnership uses ReviR’s RNA-targeted technologies to discover and develop novel, cutting-edge therapies for genitourinary (GU) tumors and other significant associated disorders. As...
Researchers discovered Dual Action Novel Compound for Cancer Treatment
Image Source:- >> | Content Source:- >> Indian scientists have discovered an alternative drug molecule, Ruthenium Ferrocene Bimetallic, which has dual action mechanism against cancer. It controls primary tumor growth antiproliferation and checks metastasis (growth) through antiangiogenesis. The new agent restricts new blood vessel development and can help treat...
Turmeric can suppress the side effects associated with Breast Cancer treatment
Image Source:- >> | Content Source:- >> Researchers from UC Davis, with the support of Safeway Foundation, decided to test if turmeric, in combination with oral anti-estrogen drugs, can mitigate the adverse effects of breast cancer treatment, such as joint pain, and explore whether it improves the quality of...
Northwest Biotherapeutics has received approval from MHRA to investigate its dendritic cell-based therapy
News Source:- >> | Image Source:- >> Northwest Biotherapeutics, a biotechnology company is focused on developing personalized immunotherapies designed to treat cancers more effectively than current available treatments. Recently, Northwest Biotherapeutics, has developed DCVax personalized immune therapies for various types of tumor cancers has received approval from the UK...
Innovent Biologics, Sanofi to develop cancer medicines for China
News Source:- >> | Image Source:- >> Innovent Biologics and Sanofi have announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers. Both companies are devoted to accelerating the development and commercialization of two key clinical-stage oncology assets from Sanofi: Phase III SAR408701 (tusamitamab ravtansine;...
CancerFree Biotech Develops World’s First Commercial System to Generate Personalized Cancer Cell Profile
News Source:- >> | Image Source:- >> Taiwanese firm CancerFree Biotech Ltd. has developed a breakthrough for patients with stage 2 solid tumor. Stage 2 patients or above shortens the drug therapy selection process through a personalized cancer profile. This is the world’s first commercial Circulating Tumor Cell-Derived Organoid...
ImmunityBio’s Bladder Cancer Immunotherapy gets an FDA Approval
News Source:- >> | Image Source:- >> ImmunityBio announced that the U.S. Food and Drug Administration has accepted its Biologics License Application (BLA) for N-803, a specific form of bladder cancer. N-803 is an antibody cytokine fusion protein. The BLA is for the use of the drug with Bacillus...
Overcoming The Challenges Of CAR T-Cell Therapy Development
In today’s world, there is no scarier disease than cancer. Cancer is often considered deadly and untreatable, supported by the fact that cancer has been one of the crucial causes of mortality globally. In 2020, there were approximately 19.3 million new cancer cases and almost 10.0 million cancer deaths....
Exscientia Announces Clinical Trials For The First AI-Designed Immuno-Oncology Drug
Strategic Development Exscientia Ltd., a leading AI-driven Pharmatech firm, announced that the world’s first AI-designed immuno-oncology molecule had entered human clinical trials. Exscientia and Evotec collaborated to co-invent and develop the A2a receptor antagonist, which is being formulated for adult patients with advanced solid tumors. Strategic Alignment Adenosine A2A...